RESEARCH TRIANGLE PARK, N.C. – May 23, 2011 – Quintiles Transnational Holdings Inc. (the “Company”), parent of Quintiles Transnational Corp. (“Quintiles”), today announced that it has extended the consent payment deadline for its previously announced tender offer and consent solicitation for any and all of the Company’s outstanding $525 million aggregate principal amount 9.50% senior notes due 2014 (CUSIP Nos. 74876Y AA9 and U74887 AA5)(the “Notes”) to 12:00 midnight, New York City time, on Tuesday, June 7, 2011, unless extended, amended or earlier terminated by the Company in its sole discretion (the “Consent Payment Deadline”).
Under the terms of the tender offer and consent solicitation, the total consideration for each $1,000 principal amount of Notes validly tendered and accepted in the tender offer will be $1,028.75, plus accrued and unpaid interest to, but excluding, the applicable settlement date. The total consideration includes a consent payment of $25.00 per $1,000 principal amount of Notes and is payable to holders who validly tender their Notes and validly deliver their consents on or prior to the Consent Payment Deadline. The tender offer and consent solicitation is scheduled to expire at 12:00 midnight, New York City time, on Tuesday, June 7, 2011, unless extended, amended or earlier terminated by the Company in its sole discretion.
The full terms and conditions of the tender offer and consent solicitation are included in the Company’s Offer to Purchase and Consent Solicitation, dated May 10, 2011, as amended hereby, and the Letter of Transmittal (collectively, the “Offer Documents”). Except as described in this press release, the terms of the tender offer and consent solicitation remain the same as set forth in the Offer Documents.
The Company’s obligation to consummate the tender offer remains conditioned upon the satisfaction of certain conditions, including without limitation, (i) Quintiles having borrowed funds sufficient to purchase the Notes tendered and pay the related consent payments and fees and expenses in connection therewith prior to expiration of the tender offer, (ii) holders of Notes representing not less than a majority in principal amount of the outstanding Notes having tendered their Notes and delivered their consents, and (iii) the execution of a supplemental indenture to the Notes’ indenture implementing the proposed amendments to that indenture.
The Company has engaged Wells Fargo Securities, LLC to act as dealer manager in connection with the tender offer. Questions regarding the tender offer may be directed to Wells Fargo Securities, LLC at (866) 309-6316 (toll-free) and (704) 715-8341 (collect). Requests for documentation may be directed to Global Bondholder Services Corporation, the tender agent and information agent for the tender offer, at (866) 470-4200 (toll free) or (212) 430-3774.
This press release does not constitute an offer to buy, the solicitation of an offer to sell or the solicitation of consents with respect to the Notes. In accordance with any state securities laws applicable to the tender offer in the United States which require the tender offer to be made to the public by a licensed broker or dealer, the tender offer shall be deemed to be made to the holders of Notes residing in those states by Wells Fargo Securities, LLC on behalf of the Company. The tender offer and solicitation of consents is made solely pursuant to the Offer Documents.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com. Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, the possibility that Quintiles may not be able to complete the financing on terms acceptable to Quintiles prior to the expiration of the tender offer or otherwise obtain funds sufficient to achieve the refinancing. Any forward-looking statements are as of the date hereof, and we have no duty to update them if our views later change.